| Literature DB >> 24179439 |
Melissa M Liu1, Chi-Chao Chan, Jingsheng Tuo.
Abstract
Epigenetics pertains to heritable alterations in gene expression that do not involve modification of the underlying genomic DNA sequence. Historically, the study of epigenetic mechanisms has focused on DNA methylation and histone modifications, but the concept of epigenetics has been more recently extended to include microRNAs as well. Epigenetic patterning is modified by environmental exposures and may be a mechanistic link between environmental risk factors and the development of disease. Epigenetic dysregulation has been associated with a variety of human diseases, including cancer, neurological disorders, and autoimmune diseases. In this review, we consider the role of epigenetics in common ocular diseases, with a particular focus on DNA methylation and microRNAs. DNA methylation is a critical regulator of gene expression in the eye and is necessary for the proper development and postmitotic survival of retinal neurons. Aberrant methylation patterns have been associated with age-related macular degeneration, susceptibility to oxidative stress, cataract, pterygium, and retinoblastoma. Changes in histone modifications have also been observed in experimental models of diabetic retinopathy and glaucoma. The expression levels of specific microRNAs have also been found to be altered in the context of ocular inflammation, retinal degeneration, pathological angiogenesis, diabetic retinopathy, and ocular neoplasms. Although the complete spectrum of epigenetic modifications remains to be more fully explored, it is clear that epigenetic dysregulation is an important contributor to common ocular diseases and may be a relevant therapeutic target.Entities:
Keywords: Age-related macular generation; Cataract; DNA methylation; Diabetic retinopathy; Epigenetics; microRNA.
Year: 2013 PMID: 24179439 PMCID: PMC3664466 DOI: 10.2174/1389202911314030002
Source DB: PubMed Journal: Curr Genomics ISSN: 1389-2029 Impact factor: 2.236
DNA Methylation and Histone Modifications in Ocular Diseases.
| Gene | Modification | Study Population | Tissue | Effect/significance | Reference |
|---|---|---|---|---|---|
| Hypomethylation of promoter region | AMD patients | Peripheral blood mononuclear cells | Increased frequency of IL-17RC+CD14+ mononuclear cells in peripheral blood | [ | |
| Hypermethylation of promoter region | AMD patients | RPE/choroid and neurosensory retina | Decreased mRNA and protein levels of GSTM1 and GSTM5 | [ | |
| Hypermethylation of CpG island at -856 to -640 | Age-related cataract patients | Lens epithelial cells | Decreased mRNA and protein levels of CRYAA | [ | |
| Hypermethylation of CpG sites at -268, -32, -29 bp | Pterygium patients | Pterygium tissue | Decreased mRNA and protein levels of TGM2 | [ | |
| Hypomethylation of CpG sites at +484 and +602 bp | Pterygium patients | Pterygium tissue | Increased mRNA and protein levels of MMP2 | [ | |
| Hypomethylation of CpG sites at -809, -762, -631, -629 bp | Pterygium patients | Pterygium tissue | Increased mRNA and protein levels of CD24 | [ | |
| Hypermethylation of promoter regions | Retinoblastoma patients | Formalin-fixed paraffin-embedded retinoblastoma tissue | Epigenetic dysregulation of tumor suppressors | [ | |
| Hypermethylation of CpG site in promoter region | Balb/c NOD SCID mice | LS174T human colon adenocarcinoma cells injected into anterior chamber | Ocular microenvironment can regulate promoter methylation and expression of | [ | |
| Increased H4K20me3 and H3K9ac at promoter and enhancer regions | Streptozotocin-induced diabetic rat | Retina | Decreased | [ |
miRNA Signatures in Ocular Diseases.
| miRNA | Modification | Study Population | Tissue | Effect/significance | Reference |
|---|---|---|---|---|---|
| miR-96, miR-182, miR-183 | Expression downregulated | Multiple mouse models of retinitis pigmentosa: rho-/-, Δ307-rds, rds-/-, P347S-Rhodopsin | Retina | These miRNAs are part of a sensory-organ specific cluster and are normally highly expressed in retina | [ |
| miR-1, miR-133, miR-142 | Expression upregulated | Multiple mouse models of retinitis pigmentosa: rho-/-, Δ307-rds, rds-/-, P347S-Rhodopsin | Retina | Unknown | [ |
| let-7 | Expression upregulated | Age-related cataract patients | Lens epithelial cells | Increased expression correlated with cataract severity | [ |
| miR-142-5p, miR-21 | Expression upregulated | Mouse model of experimental autoimmune uveoretinitis | Eye | miR-21 targets IL-12p35 | [ |
| miR-182 | Expression downregulated | Mouse model of experimental autoimmune uveoretinitis | Eye | miR-182 may target IL-17A | [ |
| miR-23, miR-27 | Locked nucleic acid-modified anti-miRNA (LNA-anti-miR) mediated knockdown | Mouse model of laser-induced choroidal neovascularization | Eye after intravitreal injection of LNA-anti-miRs | Knockdown suppresses development of retinal vasculature, protects against laser-induced choroidal neovascularization | [ |
| miR-106a, miR-146, miR-181, miR-199a, miR-214, miR-424, miR-451 | Expression upregulated | Mouse model of ischemia-induced retinal neovascularization | Retina | Unknown | [ |
| miR-31, miR-150, miR-184 | Expression downregulated | Mouse model of ischemia-induced retinal neovascularization | Retina | Intraocular injection of pre-miR-31, 150, or 184 reduces ischemia induced retinal or laser induced CNV | [ |
| miR-200b | Expression downregulated | Streptozotocin-induced diabetic rat and human diabetic retinopathy patients | Retina | miR-200b mimic prevents diabetes-induced increase in VEGF | [ |
| miR-17/92 | Expression upregulated | Human and murine retinoblastoma | Retinoblastoma tissue | Overexpression in Rb/p107 double knockout mouse accelerates retinoblastoma development | [ |